Cybin Inc. Common Stock Cash Flow Conversion Efficiency
Cybin Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Cybin Inc. Common Stock (HELP) has a cash flow conversion efficiency ratio of -0.117x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.84 Million) by net assets ($375.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cybin Inc. Common Stock (2017–2025)
Cash flow conversion efficiency of Cybin Inc. Common Stock from 2017 to 2025. This chart illustrates how Cybin Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Cybin Inc. Common Stock for real-time trading data and today's change.
Cybin Inc. Common Stock Cash Flow Conversion Ratio Explained
Cybin Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cybin Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cybin Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Cybin Inc. Common Stock (HELP) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pacific Current Group Ltd
AU:PAC
|
0.026x |
|
Acadian Timber Corp
TO:ADN
|
0.007x |
|
Kaldalón hf.
IC:KALD
|
N/A |
|
Allogene Therapeutics Inc
NASDAQ:ALLO
|
-0.094x |
|
Okins Electronics Co. Ltd
KQ:080580
|
0.113x |
|
Eaton Vance California MBF
NYSE MKT:EVM
|
0.036x |
|
Shanghai Jin Jiang International Hotels Development Co Ltd B
SHG:900934
|
0.084x |
|
MBIA Inc
NYSE:MBI
|
-0.042x |
Annual Cash Flow Conversion Efficiency for Cybin Inc. Common Stock (2017–2025)
The table below shows the annual cash flow conversion efficiency of Cybin Inc. Common Stock from 2017 to 2025. Review HELP cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $237.20 Million | $-101.30 Million | -0.427x | -80.93% |
| 2024-03-31 | $291.93 Million | $-68.91 Million | -0.236x | +76.00% |
| 2023-03-31 | $48.23 Million | $-47.43 Million | -0.983x | -65.65% |
| 2022-03-31 | $76.16 Million | $-45.21 Million | -0.594x | -168.68% |
| 2021-03-31 | $86.12 Million | $-19.03 Million | -0.221x | -23002.44% |
| 2020-03-31 | $1.45 Million | $-1.38K | -0.001x | +99.55% |
| 2019-03-31 | $394.73K | $-83.78K | -0.212x | +60.57% |
| 2018-03-31 | $440.25K | $-237.03K | -0.538x | -5701.70% |
| 2017-03-31 | $292.78K | $2.81K | 0.010x | -- |
About Cybin Inc. Common Stock
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical tr… Read more